Thierry Abribat

DVM, PhD, Founder & President
A doctor in Veterinary Medicine and a PhD from the National Polytechnic Institute of Toulouse, Thierry began his career as scientist at Sanofi-Recherche (Toulouse, France), then at University of Montreal and as a consultant to the biopharmaceutical industry. He has then held several executive positions with increasing responsibilities in drug development, business development and management at Theratechnologies (TH.TO, Montreal, Canada) and at OPi (Lyon, France), until OPi’s acquisition by EUSA Pharma Inc. He now serves as president & CEO of the Alizé Pharma Group, which he founded in 2007.

Soraya Allas

MD, PhD, Medical Director
Soraya Allas joined Alizé Pharma in June 2008. Soraya holds an M.D. from the University of Algiers and a Ph.D. in biomedical science from the University of Montréal. Over the last 15 years, she has gained international experience in drug development including preclinical and clinical research in a CRO, then at Theratechnologies (TH.TO) as director, Clinical Science and medical director. She was notably involved in the design, implementation and data analysis of Phase I, Phase II and Phase III programs and in interactions with regulatory authorities including FDA, Health Canada and EMEA.

André de Villers

MD, Member of the Board
Dr. de Villers has been closely involved in the emergence of the biotechnology sector in Quebec. From 1988 to 1993, he created and successfully managed several R&D venture capital companies, generating an investment totaling $250 million. He is the founder of Theratechnologies (TH.TO), which he served as president from 1993 to 2004.  From 2004 to 2006, he was chairman of the board and CEO of Celmed Bioscience. Dr de Villers is now the president of CEMA Inc, an independent investment company based in Montreal, Canada.

Gilles Alberici

PharmD, PhD, Member of the Board
Gilles Alberici has more than 20 years of experience in the European pharmaceutical industry as a successful entrepreneur. He is a pharmacist and doctor in Immunology. From 1994 to 1999, he founded and directed IMTIX -within Pasteur-Merieux- then IMTIX-SangStat. More recently, from 1999 to 2007, he developed OPi, Pharmaceuticals for rare diseases. From 2006, Gilles has been managing OCTALFA, a family-owned independent investment company specializing in Life Sciences, and the Dominique & Tom Alberici-OCTALFA Foundation.